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Introduction: The implementation of early long-term, regular clotting factor concentrate (CFC) replacement
therapy (‘prophylaxis’) has made it possible to offer boys with haemophilia a near normal life. Many different
regimens have reported favourable results, but the optimum treatment regimens have not been established and
the cost of prophylaxis is very high. Both for optimizing treatment and reimbursement issues, there is a need to
provide objective evidence of both short- and long-term results and benefits of prophylactic regimens. Aims: This
report presents a critical review of outcome measures for use in the assessment of musculoskeletal health in
persons with haemophilia according to the International Classification of Functioning, Disability and Health
(ICF). This framework considers structural and functional changes, activities and participation in a context of
both personal and environmental factors. Methods: Results were generated by a combination of a critical review
of available literature plus expert opinion derived from a two day consensus conference between 48 health care
experts from different disciplines involved in haemophilia assessment and care. Outcome tools used in
haemophilia were reviewed for reliability and validity in different patient groups and for resources required.
Results and conclusion: Recommendations for choice of outcome tools were made according to the ICF domains,
economic setting, and reason for use (clinical or research). The next step will be to identify a ‘core’ set of
outcome measures for use in clinical care or studies evaluating treatment.
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Introduction
The natural history of persons with haemophilia is
characterized by repeated intramuscular and intra-
articular bleeding, especially into ankles, knees and
elbows. Eventually, repeated bleeding results in
chronic synovitis and haemophilic arthropathy. Both
arthropathy and pain lead to serious disability. Since
the introduction of safe clotting factor concentrates
(CFCs), regular replacement therapy (‘prophylaxis’),
and the establishment of comprehensive care haemo-
philia treatment centres, the outcome of severe haemo-
philia has improved dramatically. However, optimal
programmes of prophylaxis are not yet established
and treatment-related complications such as inhibitor
development are a major problem. Furthermore, many
patients still have limited access to treatment and even
in resource unconstrained countries some patients con-
tinue to experience joint damage despite prophylaxis.
Consequently, clinicians still are striving to optimize
treatment, which can only be achieved through
prospective evaluation of different CFC replacement
protocols, longitudinal cohort studies, and the use of
reliable, valid and sensitive outcome assessments.
Standardization of outcome assessment will permit
meaningful comparison across studies and reduce
heterogeneity in knowledge acquisition in this rare but
expensive to treat condition.
Outcome assessment is a complex undertaking
involving many factors. To include the full spectrum
of consequences of a disease, outcome assessment
should follow the WHO proposed International Clas-
sification of Functioning, Disability and Health (ICF)
[1]. ‘This model provides a framework to qual-
ify the different interactive components of the main
disease-disability pathway: Body Functions and Struc-
tures, Activities, Participation, and Environmental and
Personal factors. Each of these components is further
categorized and coded. Several factors need to be con-
sidered while assessing functioning and disability in
this manner. First, in a chronic condition such as hae-
mophilia it is important to consider the time window
of observation. In haemophilia, the time of observa-
tion ranges mostly from a minimum of 6–12 months
(e.g. for assessment of bleeding), to decades or even
lifelong (e.g. for assessment of musculoskeletal results
of prophylaxis). Second, it is important to consider
the specific aim (i.e. perspective) of the outcome
assessment. While patients and health care providers
are both interested in achieving optimum treatment
outcomes, it is the patient that faces the burden of
treatment and this may lead to different perspectives.
At the same time, health outcomes research is used to
inform decisions regarding reimbursement of treat-
ment. These economic studies evaluate patient relevant
outcomes of the health care process in the real-life
world; this includes the patient’s functional status,
well-being and satisfaction with care, as well as direct
medical costs and days lost from work/school. These
data are used for cost-effectiveness or cost-utility anal-
yses to compare the value of different treatment
strategies.
The aim of this initiative was to provide an evi-
dence-supported expert review on tools to use for out-
come assessment in haemophilia care and research,
including different settings and perspectives.
Methods
The present review is based on face-to-face group dis-
cussions among 48 multidisciplinary experts from
North America (n = 25), Europe (n = 11) and other
countries (n = 12. Disciplines represented included
haematology, orthopaedic surgery, physical therapy,
physiatry, radiology, ultrasonography and health eco-
nomics. A list of meeting attendees is provided in the
Acknowledgements section.
Separate discussions were held on four topics in out-
come assessment of health: (i) physical examination,
(ii) imaging, (iii) activity and participation, and (iv)
health economics and quality of life.
During the discussions, available literature on mea-
surement properties and tools was identified. In addi-
tion, full text original articles in English (PubMed)
pertaining to development, validation, and ability to
discriminate between haemophilia patient groups were
considered for each tool. Summary reports for each
topic identified the following characteristics: classifica-
tion (generic/disease specific), target population for the
tool (age, and/or extent of joint damage), setting (clin-
ical care and/or research), assessment time, validation
and discriminative abilities of the tool, optimum inter-
val between assessments, remarks regarding additional
research, and final recommendation (mandatory,
recommended, optional, limited value, unknown).
Results
Bleeding
As the main symptom of haemophilia, bleeding fre-
quency is the primary parameter for treatment deci-
sions. Standard assessment of bleeding frequency
considers the number of bleeds optimally collected
over a period of twelve consecutive months (annual-
ized bleeding rate or ABR). This parameter suffers
from many caveats, limiting its usefulness for both
clinical practice and research. First, the diagnosis of a
bleeding episode is generally subjective and based on
patient (or proxy) reported symptoms. Most bleeds
are not confirmed by health care providers as patients
with severe haemophilia usually treat bleeding epi-
sodes at home. Thus, lack of a gold standard and/or
objective assessment may result in over-or under-
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reporting of bleeds. Under-reporting will be worse in
patients who fail to keep adequate diaries. Especially
soft tissue and minor bleeds are likely to be underre-
ported. In patients with haemophilic arthropathy, pain
related to pre-existing arthritis may be misinterpreted
as bleeds. Major and life-threatening bleeds requiring
immediate medical attention are easier to capture.
Documentation of bleeds by either patients or health
care providers should be performed according to pre-
specified definitions. Published definitions [2,3] of
bleeds focus on location and symptoms of bleeding
without distinguishing between major and minor
bleeding. The PedNet group have added severity to
the previous definitions: (i) a major bleed is defined as
‘a bleed characterized by pain, swelling, restriction of
motion and failure to respond within 24 hours of
treatment’; and (ii) a minor bleed is ‘characterized by
mild pain, minimal swelling, minimal restriction of
motion, and resolving within 24 hours of treatment’
[4]. In both cases, treatment response is defined as a
complete resolution of symptoms.
As bleeding rates on prophylaxis or in persons with
mild/moderate haemophilia are generally low, it is rec-
ommended to collect bleeding data prospectively, for
a minimum of 12 months to produce reliable annual
bleeding rates. In addition to ABR, annual joint bleed
rates (AJBR) should be reported. Furthermore, it is
recommended to distinguish between major and minor
bleeding, between provoked (i.e. traumatic) and
unprovoked bleeding, as well as between target joint-
or non-target joint bleeding. The distinction between
provoked and unprovoked bleeding may be difficult in
young children who are often unable to verbalize that
trauma has occurred. Target joints have been defined
as joints suffering three or more spontaneous bleeds
within six months [3] and their presence often drives
high AJBR.
Musculoskeletal outcome: structure and function
Joint health based on physical examination. Joint
function assessed by physical joint examination per-
formed by an experienced health care professional is
often used as the primary outcome for haemophilic
arthropathy. Tools and scores for objective physical
assessment of joint health are shown in Table 1. Joint
health of the ankles, knees and elbows, was first
assessed by collecting Active Range of Motion
(AROM) [5], which was followed by the World Fed-
eration of Haemophilia (WFH) Orthopaedic Joint
Score (or Clinical Score) described by Gilbert [6].
Although widely used in clinical and research studies,
the Gilbert score was never designed for use in
(young) patients with minimal arthropathy, and was
never formally validated. Investigators in the USA
(Colorado) and Sweden (Stockholm) independently
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These instruments were combined by the International
Prophylaxis Study Group (IPSG) into a single joint
score focused on the detection of early joint changes
in young boys with haemophilia. This new joint scor-
ing instrument, the Haemophilia Joint Health Score
(HJHS), was the first to undergo formal reliability and
validation studies in boys with haemophilia ages
4–18 years [8,9]. Following initial development sev-
eral changes were made, resulting in the current ver-
sion (HJHS 2.1) consisting of 8 items and a global
gait score.
As expected, the HJHS is more sensitive to early
joint changes than the Gilbert score [9]. It can distin-
guish between different prophylactic strategies in
young adults with severe haemophilia [10], between
severe and non-severe haemophilia in children [9,11]
and is responsive to changes following physiotherapy
treatment [12]. However, it is so sensitive that it
showed positive scores in 40% of unaffected young
adults (total score ≤ 3 points) [13].
Administering the HJHS requires training and
experience in joint assessment. A teaching video and
instruction manual in multiple languages are available
on-line (www.ipsg.ca) [14–16]. For comparative stud-
ies including multiple raters, it is recommended that
physiotherapists initially score patients together and
harmonize scoring as there is evidence for consider-
able inter-rater variability of routinely collected
scores [17]. For the HJHS version 2.1 (maximum
total score 124 points), the first data on the limits of
agreement between raters show values of 9.6 points
for children [18,19] and 6.4 points for young adults
[20].
Imaging studies. While bleeding, function and pain
drive most clinical decisions in haemophilia care,
imaging offers an objective assessment of joint struc-
tural outcome that can be compared directly within or
between patients. Imaging tools for assessment of
haemophilic joint changes are shown in Table 2.
Historically, plain radiographs of the ankles, knees
and elbows were used to quantify the severity of hae-
mophilic arthropathy. Using almost identical items,
two scoring systems were developed; one progressive
(Arnold and Hilgartner [21]), the other additive (Pet-
tersson [22]). Although both can be used in clinical
practice to assess changes in individual patients, the
Pettersson score has been more widely used in
research as it allows evaluation of detailed changes.
The Pettersson scoring system has excellent reliability
when used by radiologists experienced in reading mus-
culoskeletal images [23]; a recently developed scoring
atlas is likely to further improve scoring reliability
[24]. In young adults, correlations between Pettersson
scores and HJHS are strong [25].
Over the past few decades the ability to assess soft-
tissue changes has improved dramatically.
Magnetic Resonance Imaging (MRI) is more sensi-
tive than plain radiography for detection of early soft-
tissue changes including synovial hypertrophy, hemosi-
derin deposition and early osteochondral changes in
persons with musculoskeletal disease [26]. In parallel
with the X-ray scoring systems, MRI scoring started
with a progressive [27] and an additive scoring system
[28]. These were subsequently combined into a single
MRI scoring system with good measurement proper-
ties by the Imaging Expert Working Group of the
International Prophylaxis Study Group (IPSG) [29,30].
Studies on MRI in healthy young males playing sports
[31,32], healthy children [33], and children with hae-
mophilia [30,34] have recently been published. In
addition, following reports of MRI changes in joints
without any reported bleeds [35,36] there is a growing
interest in the association of bleeding history with
MRI changes [37–40]. However, MRI has practical
disadvantages such as difficulties in standardizing
MRI-scanner settings according to different MRI man-
ufacturers, long scanning time required, high cost, lim-
ited availability, and the need for sedation in young
children. These aspects limit the widespread use of
MRI for research and assessment of specific clinical
situations such as unexplained complaints or
pre-operative assessment [41].
Ultrasound is a useful modality for assessing muscu-
loskeletal disease in persons with haemophilia (PWH),
especially for the evaluation of soft-tissue changes
such as synovial hypertrophy and peripheral cartilage
changes; its ability to detect acute bleeding (i.e. distin-
guish between bloody and serous effusion) and hae-
mosiderin deposits has been debated [42–45].
Compared to MRI, it offers advantages such as lower
cost, better availability, no need for sedation, and a
shorter examination time. In addition, ultrasound can
be incorporated into haemophilia clinic visits allowing
real time feed-back to patients. Disadvantages include
a high degree of operator dependency and inability to
assess the deeper central part of joints, as well as the
time needed for assessment using full diagnostic proto-
cols. Standardized protocols for ultrasound assessment
of ankles, knees and elbows have been published [46–
48] and tested against MRI [34,49,50]. Recently,
Martinoli and colleagues have reported details of a
simplified ultrasound scanning protocol and scoring
system – the Haemophilia Early Arthropathy Detec-
tion with Ultrasound (HEAD-US) [51]. This scoring
system is specifically developed for point of care use
by non-radiologists and can be practiced after a short
training period. It evaluates synovium, cartilage and
bone, resulting in a total score ranging from 0 (no
changes) to 8 points (severe changes). The inter-opera-
tor reliability among 5 haematologists was high with
an intraclass-correlation of 0.72 (95% CI 0.62–0.82)
[52]. Although promising, the HEAD-US method
requires validation against physical examination,
Haemophilia (2017), 23, 11--24 © 2016 The Authors. Haemophilia Published by John Wiley & Sons Ltd.
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radiography, full diagnostic ultrasound and MRI in a
large series of individuals with haemophilia and vary-
ing degrees of arthropathy. Overall, the value of ultra-
sound in clinical practice and research remains to be
determined [42,53]. While not representing joint func-
tion, imaging of soft tissue and cartilage may offer an
opportunity for earlier intervention to limit osteochon-
dral damage.
Musculoskeletal outcome: activities and
participation
Activities and participation are very closely related:
according to the ICF model an activity is defined as
‘the execution of a task or action by an individual’
while participation encompasses ‘involvement in a life
situation’. Measurements of activities and participa-
tion used in haemophilia are shown in Table 3, these
include both objective and self-reported assessments.
Objective assessment of activities. The patient per-
spective of outcome is concerned with functional
physical ability and social participation. A few tools
(haemophilia specific and generic) have been used to
objectively assess the ability of PWH to perform
certain tasks (Table 3).
The only disease-specific tool currently available is
the Functional Independence Score for Haemophilia
(FISH), which was developed in India to assess the
functional ability of individuals with haemophilia to
perform activities of daily living [54,55]. The assess-
ment can be performed after a short training session
and does not require advanced skills of physical exam-
ination. The FISH includes eight activities in three cat-
egories: self-care (eating and grooming, bathing and
dressing), transfers (chair and squatting) and locomo-
tion (walking, climbing stairs and running). Each
activity is scored according to the amount of assis-
tance required to perform the task [54]. The FISH has
been validated (in 63 patients aged 7–40 years) and
was able to discriminate between patients and healthy
controls and between different levels of severity of
haemophilia [56,57]. However, the FISH shows a ceil-
ing effect in subjects with only limited arthropathy
[12]. Development of an updated version (eFISH)
including more demanding activities is currently
underway (P Poonnoose, personal communication).
The other generic instruments for objective assess-
ment of activities listed include gait analysis and func-
tional tests [58–60]. Three-dimensional gait analysis
(3DGA) provides information on the functional per-
formance of arthropathic joints. However specialized
equipment is required for measuring kinematic, kinetic
and the temporal spatial gait parameters [58,59].
Generic instruments for assessment of activities are
primarily focused on mobility and physical movement.
Generic instruments used in haemophilia include the
Figure 8 test, originally part of the Timed Movement
Battery, developed to evaluate mobility in the elderly.
For the adapted Figure 8 test, a patient is asked to
walk a Figure 8 around two pylons placed at a
5-metre distance, at a preferred speed and at a maxi-
mum speed. However, this test showed no correlation
with self-reported limitations in activities [61] and
was too insensitive to distinguish between adults who
discontinued and those who continued prophylaxis
[62].
The Six Minute Walk Test (6MWT) reflects aerobic
capacity in patients without musculoskeletal disease,
and is expected to reflect both aerobic capacity and
joint function in patients with haemophilia. The 50-
metre walking test (50WT) generally takes less than
1 minute, and is expected to be mostly sensitive to
musculoskeletal changes. There is some experience
with both the 6MWT and 50WT tests in haemophilia
[12,61,63,64], including limited evidence that espe-
cially the 6MWT is able to discriminate between pae-
diatric patient groups. Accelerometry has been used
for objective assessment of the intensity and duration
of physical activity in haemophilia in a limited num-
ber of studies to date [65,66]. Although most current
accelerometers provide no information on the specific
physical activities or the risk of associated injury, new
devices that can distinguish between lying, sitting,
standing, walking, cycling and running are being
developed.
Indirect ‘objective’ assessment of activities and par-
ticipation is provided by registration of work partici-
pation and days lost from work or school due to
haemophilia. These parameters can also be used for
economic evaluations [67].
Self-reported assessment of activity and participation-
disease-specific instruments. The Haemophilia Activi-
ties List (HAL) is a questionnaire developed from
interviews with Dutch patients. It assesses self-
reported limitations in activities in adults [68]. A pae-
diatric version for children aged 8–18 years (ped-
HAL), including a proxy version to be completed by
parents/caregivers of children aged 4–12 years, is also
available [69]. The questionnaire has seven domains:
lying/sitting/transferring/standing (i), leg functions (ii),
arm functions (iii), use of transportation (iv), self-care
(v), household tasks(vi), and leisure activities/sports
(vii). In addition to domain-scores, it generates four
summary scores: (i) upper extremities, (ii) lower
extremities, (iii) complex lower extremities, and (iv)
sum score. The internal consistency and convergent
validity of the HAL were tested in 211 adults [61,70]
and 133 children from various European countries
and Brazil; this showed good measurement properties
with the exception of some variability in test–retest
agreement in children [12,71]. The HAL is easy to use
and available in many languages. In patients treated
Haemophilia (2017), 23, 11--24 © 2016 The Authors. Haemophilia Published by John Wiley & Sons Ltd.
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with early prophylaxis, the HAL was able to discrimi-
nate between different prophylactic regimens [10], but
the high proportion of both children and adults with
maximum scores (ceiling effect) can be a limitation to
the instrument [12,25,69]. As a tool developed in
Western Europe, there are certain nuances in the items
that are culturally dependent and may not adapt well
to other countries/regions without cultural adaptation
[12,54]. Finally, items on participation are underrepre-
sented in both the HAL and pedHAL and may be best
captured in a separate questionnaire.
Self-reported assessment of activity and participation-
generic instruments. For day-to-day patient manage-
ment, the Canadian Occupational Measure (COPM)
[72] and the McMaster Toronto Patient Disability
Questionnaire (MACTAR) [73] can be very useful.
Both instruments are administered as a semi-struc-
tured interview to assess the patient’s perception in
their actual performance in various activities and their
satisfaction with this performance over time. Both
include identification of key activities in daily life that
a patient wishes to improve upon. The targeted activi-
ties can be used to both guide and evaluate interven-
tions. The COPM has been validated for haemophilia
care [74] and the MACTAR was used in the develop-
ment of the HAL questionnaire [68].
Although several age-specific generic participation
questionnaires are available, only the Impact on Par-
ticipation and Autonomy (IPA [75]) questionnaire has
been used in haemophilia research [76,77]. This tool
scores five domains: (i) autonomy indoors, (ii) auton-
omy outdoors, (iii) family role, (iv) social role and (v)
work and education. It is focussed on independence in
performing certain activities (autonomy), rather than
on the ability to perform a certain activity. The IPA
has no summary scores.
Parameters for economic evaluation
Due to the high cost of treatment, economic evalua-
tion is important in both haemophilia research and
care. Economic evaluations of health care measure
both outcome and costs of therapy. Key parameters
for economic evaluation are shown in Table 4.
A cost-utility analysis estimates cost per quality-
adjusted life year (QALY); it is the decision makers’
preferred tool to assess the value of interventions. Costs
are expressed in monetary terms, while QALYs repre-
sent the value of outcome. QALYs are a composite
measure, which take into consideration both an individ-
ual’s lifespan (in years) and preferences for different
health states reflected in quality of life (QOL). Prefer-
ences are expressed as a value between 0 (equivalent to
death) and 1 (a value signifying perfect health) [78]. A
disease-specific tool for utility measurement in haemo-
philia has been developed but has not been applied in
research [79]. All published research to data have used
the generic EuroQol questionnaire (EQ5D) [80]. From
its five questions, the utility value is calculated accord-
ing to a local tariff. The UK tariff is used most fre-
quently [81]; however, any tariff is a valuation of
health states and therefore is culturally dependent
Potential differences must be taken into account for the
interpretation of international comparisons. In adults
with haemophilia, utility values were able to distinguish
between patients treated on demand and those treated
on prophylaxis [82–84], but not between patients trea-
ted with different prophylactic regimens [10]. Recently,
a paediatric version of the EQ5D was developed
(EQ5D-Y), but this has not yet been used in boys with
haemophilia [85,86]. For adults, utility values can also
be derived from the generic Short Form 36 (SF36) ques-
tionnaire [87]; this derivation is the named the SF6D
[88,89]. The SF36 has been widely used in haemophilia,
and the first studies using the SF6D were recently pub-
lished [90,91]. Although these instruments provide a
way for comparing overall impact of the disease and
the care provided in a socio-economic context, their use
for the evaluation of management in individual patients
is limited [92]. When comparing results of different
cohorts managed with different treatment protocols,
the added value of Utilities is limited compared to sig-
nificant differences in clinical outcome. These data are
therefore more useful when comparing outcomes
between different diseases; in such a context the data
can be very useful for advocacy and lobbying efforts.
With respect to costs, clotting factor consumption
accounts for >90% of direct medical costs; therefore, it
is generally considered to be the most important param-
eter for economic evaluations [10,67,93]. Additional
direct medical costs to be considered include the cost of
clinic visits, hospital admissions, orthopaedic surgery
and days in hospital. For economic evaluations from a
societal perspective, indirect costs including days lost
from work/school for both patients and caregivers
should be considered, as should the costs of disabilities
and missed enjoyment of leisure/sports activities.
Recommended and/or mandatory outcome
parameters
Based on the group discussions and the literature, a
list of recommended and/or mandatory outcome
parameters in haemophilia according to field of use
and ICF domain was generated by the authors and is
shown in Table 5. When choosing instruments, it is
very important to consider the aim of the assessment,
patient characteristics and setting. The setting includes
aspects such as access to replacement therapy and the
use of prophylaxis. The age of the population and the
duration of follow-up should also be considered. Age
should always be included in the analyses as joint
changes are highly dependent on the bleeding history
Haemophilia (2017), 23, 11--24 © 2016 The Authors. Haemophilia Published by John Wiley & Sons Ltd.
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and the cumulative number of bleeds, even in patients
on intensive, high-dose prophylaxis [48,49]. Likewise
treatment history, that is, age at diagnosis, age at first
treatment, details of prophylaxis and a history ortho-
paedic surgery should always be included in the evalu-
ation and interpretation of results.
Discussion
It is recognized that standardized, validated outcome
assessments of haemophilia are essential for clinical
management of the individual patient, as well as for
research to develop and optimize new therapies. Out-
come assessment tools range from measures of joint
structure and function to activity capacity, social par-
ticipation and economic cost/benefit; some are con-
structed from the perspective of the haemophilia
health care provider while others are based in the
perspective of the patient. Most are suitable to
describe representative groups of patients, while a
few are rooted in individual goals and values. From
the myriad of outcome tools and parameters dis-
cussed, it is clear that the eventual choice should
depend on the aim of outcome assessment, the set-
ting, the age of the patient, joint status and the dura-
tion of follow-up.
Data collection from different perspectives
For clinical management and research, information on
treatment, bleeding (ABR and AJBR) and clotting fac-
tor consumption should be collected at least annually,
and preferably prospectively. Clinical follow-up
should always include a regular physical examination
with a standardized instrument (e.g. the HJHS). Imag-
ing studies remain optional for clinical management,
as it is not clear how much these contribute to
treatment modification in day-to-day practice. How-
ever, utilization of imaging is expected to increase as
more information becomes available.
For research, however, aspects of cultural (in)depen-
dence and inter-rater reliability become more impor-
tant in the choice of outcome parameters. In addition,
it is important to consider the duration of follow-up –
for example, studies with one year follow-up are unli-
kely to show differences in physical examination
scores or imaging scores, or activity scores, but may
show clear differences in bleeding rates, clotting factor
consumption and/or activity.
When using a combination of different outcome
tools, it is important to combine objective and
patient-reported outcomes (PRO). Objective parame-
ters may be considered less relevant for patients; a
patient may not notice a clinical difference in func-
tioning if he has minimal changes on the HJHS score
or Pettersson score [94]. However, patients may also
under-report limitations due to the phenomenon of
‘response-shift’ [95]: patients get used to certain limi-
tations and therefore report less burden despite similar
or increased objective limitations [62,96]. In this
regard, objective reporting of activities and exercises
performed, work participation and the like can pro-
vide an objective basis for comparison over time and
with other patients. An issue to be considered with
PROs, is that questionnaires are dependent on literacy
and cultural issues, and that in addition to simple
translation, cultural adaptation may be required.
Comparison with the literature
The present review performed a broad assessment of
available tools and their optimal use in specific situa-
tions, and many of its recommendations are in agree-
ment with previous reports. The recent WFH
Table 5. Recommended and/or mandatory outcome parameters in haemophilia according to field of use and ICF domain.
ICF domain Tool Clinical Research Comments
Joint function and structure Bleeding M M – At least an annual review of bleeding
– Reporting on periods of no less than 12 months
– Use recommended definitions
Physical examination M M – HJHS v2.1 when including patients with early joint
changes (all paediatric studies)
– If using HJHS is impossible, collect AROM
Imaging O R – US or MRI for evaluation of early changes
– Pettersson score (X-ray) for advanced osteochondral
changes (interval no shorter than 3 years)
Activities Observed activities R O/R – FISH in populations with more advanced joint disease
Self-reported activities R R (adults)
R (children)
– HAL, from age 18 upwards
– pedHAL, from age 4 onwards
Participation Days lost from school/work M M
Paid employment M M Include information on full-time yes/no
Economic Clotting factor consumption M M Combine with body weight and treatment regimen
Haemophilia-related surgeries M L Not for short term studies
Hospital visits M O/R
Days in hospital. M O/R
Utility assessment O R/M Not for short term studies
Choice of tariff (calculation method) affects results
M, mandatory; O, optional; R, recommended; L, limited value; U, unknown; NR, not recommended.
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treatment guidelines make no stringent recommenda-
tions, but list tools for physical and radiological exami-
nation, for assessment of activities, and for assessment
of disease-specific QOL [97]. Based on a series of con-
sensus meetings, de Moerloose et al. published recom-
mendations for assessment, monitoring and follow-up
in haemophilia [98]. The recommendations included
collection of detailed information on bleeding, clotting
factor consumption and activities including the HAL.
The HJHS and AROM were recommended for joint
assessment while imaging studies were considered
optional. The EQ-5D was recommended for economic
evaluation. Based on a Delphi process, Nicholson et al.
provided recommendations regarding reporting of eco-
nomic evaluations of prophylaxis [67]. For cost data,
this group recommended collecting clotting factor con-
sumption, number of hospitalization days, surgical pro-
cedures and productivity. For outcome assessment,
their minimum recommendation was to assess generic
utility (EQ-5D), while collection of disease-specific
QOL, joint bleeding, and joint status (HJHS) was con-
sidered optional. A recent commentary on the role of
QOL assessment recommended that the choice of out-
come tools should be dependent on access to treatment
(particularly clotting factor concentrates), use of pro-
phylaxis and joint status. It was suggested that outcome
assessment should focus on joint health, activities, and
participation, rather than on QOL only [94].
The added value of this review lies in the provision
of separate recommendations for a clinical and a
research perspective, as well as providing priorities for
certain outcome parameters.
Unresolved issues and future developments
In a disease as rare as haemophilia, international col-
laboration is mandatory to advance the field and
enable research on optimal treatment strategies. Both
treatment and outcome should be captured. Standard-
ization of outcome assessment is key; it is clear that
inter-observer variation of assessment is an issue in
the HJHS and in imaging. For the HJHS, this may be
resolved by training and for imaging studies by the
use of atlases. This was corroborated by observations
that at least one joint training session among physio-
therapists harmonized performance and scoring of the
HJHS [14,15,17,20]. For questionnaires, the issues of
literacy and cultural validation should be considered –
for example, performing household chores may be rel-
evant to men in some cultures [12,55]. Questionnaires
should be translated according to the procedures
described by the World Health Organisation (http://
www.who.int/substance_abuse/research_tools/translati
on/en/). Cross-cultural validation is also recom-
mended, but this is more important in assessment of
QOL than in assessment of physical activities.
In general, the time and burden for the patient asso-
ciated with outcome assessment should be considered.
Ideally, one would have a set of very short and concise
assessments and/or questions that are able to detect
changes within patients over time and discriminate
between different groups. One strategy to achieve this
goal for PRO is the use of Computer Adaptive Testing
(CAT): relevant questions are selected from patient
based responses to previous questions [99]. As a result,
all relevant information is collected and the number of
questions is minimized. However, this technique
requires on-line platforms, collection of extensive item
pools and calibration studies. At this time, there is no
experience using CAT in comparative studies of PWH.
Recent developments in treatment such as longer
acting CFC, gene therapy or bypassing agents are unli-
kely to affect our choice of outcome tools as bleeding
and its consequences will remain the main symptoms
of haemophilia.
Use in other bleeding disorders
For conditions other than haemophilia, the applicabil-
ity of the suggested outcome parameters and tools will
depend on the clinical phenotype of the bleeding dis-
order. In conditions resulting in joint bleeding, many
of the recommended tools can be used in clinical prac-
tice, but their validity should be established before
using them for research. For conditions resulting in
bleeding in other locations, limitations in activities,
participation, pain and eventually Health Related
Quality of Life can be collected. Again, age and treat-
ment history should be included in the analyses.
Conclusion
Outcome assessment in haemophilia should be per-
formed for clinical care purposes and/or for research.
Minimum data to be collected for both clinical use
and research are bleeding, self-reported and objective
joint function and activities, information on work and
school participation, clotting factor consumption,
health care services utilization and patient preferences.
Identification of the optimum ‘tool box’ for outcome
assessment may promote objective and PRO assess-
ment and may speed up the generation of information
on treatment outcomes in persons with haemophilia.
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